The calcium-sensing-receptor agonist, AMG 416, has previously been shown to lower plasma parathyroid hormone levels in uraemic animals and in healthy individuals. Now, researchers report that treatment with the agent was well tolerated and resulted in dose-dependent decreases in the levels of serum parathyroid hormone, fibroblast growth factor 23 and serum calcium in 28 patients with secondary hyperparathyroidism on haemodialysis. They conclude that AMG 416 therapy may be a novel way of treating secondary hyperparathyroidism in haemodialysis patients.
ORIGINAL RESEARCH PAPER
Martin, K. J. et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int. doi:10.1038/ki.2013.289
Rights and permissions
About this article
Cite this article
Efficacy of AMG 416 in patients with secondary hyperparathyroidism on haemodialysis. Nat Rev Nephrol 9, 554 (2013). https://doi.org/10.1038/nrneph.2013.155
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.155